Pharma Q1 Results Preview: Strong Sales Expected, But Margins Could Shrink; Know Why Goldman Sachs Is Cautious

India's pharmaceutical sector is expected to begin the June quarter (Q1 FY27) on a healthy note, with most leading drugmakers likely to report better sales driven by steady domestic demand and continued momentum in exports. However, investors may need to look beyond headline revenue numbers, as profitability could remain under pressure despite improving business activity.

Pharma Q1 Results Preview: Revenue Growth Likely, But Profit Margins May Shrink

A preview by global brokerage Goldman Sachs suggests that while the top line may improve, earnings growth could be weaker than expected because companies are facing higher manufacturing and logistics costs. At the same time, a major source of high-profit earnings from the US market is gradually fading, making it more difficult for several Indian pharmaceutical companies to maintain earlier profit levels.

Goldman Sachs Pharma Outlook: Indian Pharmaceutical Companies May Report Better Sales in Q1

The domestic pharmaceutical market remained healthy during the April-June quarter, supported by higher medicine demand, price increases and the launch of new products. Better demand for chronic therapies, along with the introduction of medicines such as Semaglutide-based products, is expected to support revenue growth for many companies.

Apart from India, exports are also expected to remain stable, helping large pharmaceutical companies post healthy sales growth during the quarter.

Why Pharma Profit Margins Could Decline Despite Higher Revenue

Although revenue is expected to improve, Goldman Sachs believes profitability may tell a different story. According to the brokerage, operating margins across the sector could decline by nearly 185 basis points compared to the same period last year.

The biggest reason is the gradual decline in earnings from gRevlimid, a high-margin generic cancer drug that had significantly boosted profits for several Indian pharmaceutical companies over the past few years. As competition increases and those opportunities reduce, companies are likely to lose an important source of premium earnings.

At the same time, manufacturers are also facing rising input costs. Prices of raw materials have increased, while freight and shipping expenses have climbed because of disruptions caused by the ongoing tensions in the Middle East. Higher transportation and insurance costs are making exports more expensive, putting additional pressure on margins.

Domestic Business May Provide Stability

Goldman Sachs believes companies with a stronger presence in the Indian market could be relatively better placed than those heavily dependent on the US generic business.

India's pharmaceutical market continued to expand during the quarter, with industry growth estimated at around 11.6%. Growth was supported by higher medicine prices, increasing prescription volumes and new product launches.

Many pharmaceutical companies have also indicated that demand in the domestic market remains healthy, particularly in chronic disease therapies, which continue to witness steady prescription growth.

US Generic Business Still Important, But Challenges Remain

The United States continues to be one of the largest overseas markets for Indian pharmaceutical companies, but it is also becoming increasingly competitive.

Prices of generic medicines usually decline as more manufacturers launch similar products. Although Goldman Sachs noted that overall price pressure remains relatively stable at present, companies are unlikely to enjoy the exceptional profitability seen in previous years when limited competition allowed them to earn significantly higher margins.

The brokerage believes future growth in the US market will increasingly depend on companies launching more complex medicines, speciality products and difficult-to-manufacture generics rather than relying on traditional generic drugs.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.